INSIGHTS ON DRUG DEVELOPMENT

• From 51% Yield To 87% With Targeted Impurity Removal

  Targeted impurity identification and purification redesign dramatically improved yield, reduced process complexity, and enabled reliable API supply for Phase II clinical development.

• Automated Bioburden Testing Solution

  Automation is transforming microbial quality control labs, boosting productivity, minimizing errors, and ensuring data integrity. Discover how digitalization is driving Pharma 4.0 and reshaping lab workflows.

• Navigating Emerging Therapeutics: Cannabinoid And Psilocybin Drug Development

  Cannabinoid and psilocybin therapies are advancing rapidly, and Mikart supports innovators with DEA-licensed facilities, formulation expertise, regulatory guidance, and manufacturing capabilities from clinical development to commercialization.

• API In Capsule Vs. The Lost Art Of Formulation Development

  API-in-capsule offers a fast path for early clinical data, but it can't eliminate the need for full formulation development. Weighing the potential for higher total development time and cost is critical.

• Evaluating Compound Toxicity Effects On Healthy Intestinal Organoids

  3/24/2025

  3D organoids enhance drug toxicity prediction and are crucial for anti-cancer drug development. Examine a method using 3D mouse intestinal organoids that aims to provide vital data on intestinal toxicity.

• White Paper: Characterization Of Spray Dried Biologics

  5/7/2025

  Discover how spray drying can transform the formulation of complex biologics by improving stability, delivery, and functionality, with insights into the critical techniques and strategies needed for successful development.

• This Is Where Quality Starts

  3/20/2026

  Quality takes shape long before a workcell ships. Meet the people and processes that ensure consistent performance through every stage of development, and explore how to build reliability into each step.

• The Patent Cliff Looms – Design Your Biosimilar Approach Accordingly

  3/3/2025

  In your pursuit of developing a high-quality biosimilar, think strategically. Consider what type of biologic your team’s expertise can support and which is needed most in your target market.

• Maximizing Laboratory Efficiency With Automated Dual-Thermal Cycling

  3/26/2026

  Accelerate tRNA lead discovery with automated digital PCR. Process 384 samples daily with minimal hands-on time, using dual thermal cyclers to scale from in vitro screening to clinical trials.